TABLE OF CONTENTS
1 INTRODUCTION 25
1.1 OBJECTIVES OF THE STUDY 25
1.2 MARKET DEFINITION 25
1.3 OVERVIEW OF THE GLOBAL BRAIN CANCER DIAGNOSTIC MARKET 25
1.4 CURRENCY AND PRICING 27
1.5 LIMITATIONS 27
1.6 MARKETS COVERED 27
2 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 30
2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 DBMR TRIPOD DATA VALIDATION MODEL 33
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.6 MULTIVARIATE MODELLING 37
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 37
2.8 DBMR MARKET POSITION GRID 38
2.9 VENDOR SHARE ANALYSIS 40
2.10 MARKET END USER COVERAGE GRID 41
2.11 SECONDARY SOURCES 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 46
4.1 PESTEL ANALYSIS 48
4.2 PORTERS FIVE FORCES 49
5 EPIDEMIOLOGY 50
6 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, INDUSTRY INSIGHT 51
7 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, REGULATIONS 52
7.1 REGULATORY SCENARIO IN THE U.S 52
7.2 REGULATORY SCENARIO IN AUSTRALIA 53
7.3 REGULATORY SCENARIO IN JAPAN 53
7.4 REGULATORY SCENARIO IN CHINA 53
8 MARKET OVERVIEW 55
8.1 DRIVERS 57
8.1.1 RISING CASES OF BRAIN CANCER WORLDWIDE 57
8.1.2 RISING AWARENESS OF THE EARLY DIAGNOSIS OF BRAIN CANCER 57
8.1.3 IMPROVED IMAGING TECHNIQUES 58
8.1.4 INNOVATIONS IN DRUG DELIVERY TO BRAIN CANCER CELLS 58
8.2 RESTRAINTS 59
8.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS & TREATMENT FOR BRAIN CANCER 59
8.2.2 SIDE EFFECTS OF BRAIN CANCER TREATMENT DRUGS & THERAPIES 59
8.2.3 LATE DIAGNOSIS OF BRAIN CANCER RESULTING IN POOR PROGNOSIS 60
8.3 OPPORTUNITIES 60
8.3.1 INCREASING INVESTMENT AND FUNDING BY EMERGING PLAYERS 60
8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTIC 60
8.3.3 RISING HEALTHCARE EXPENDITURE 61
8.4 CHALLENGES 62
8.4.1 STRINGENT REGULATORY REQUIREMENTS FOR DIAGNOSTIC PRODUCTS 62
8.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 62
9 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE 63
9.1 OVERVIEW 64
9.2 IMAGING TEST 67
9.2.1 CT SCAN 68
9.2.2 MRI 68
9.2.3 PET 68
9.2.4 OTHERS 68
9.3 MOLECULAR TESTING 69
9.4 ELECTROENCEPHALOGRAPHY (EEG) 69
9.5 LUMBAR PUNCTURE 70
9.6 BIOPSY 71
9.6.1 OPEN BIOPSY 72
9.6.2 STEREOTACTIC BIOPSY 72
9.6.3 NEEDLE BIOPSY 72
9.6.4 NEUROENDOSCOPY 72
9.7 OTHERS 72
10 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE 73
10.1 OVERVIEW 74
10.2 GLIOBLASTOMA MULTIFORME 77
10.3 MENINGIOMAS 78
10.4 ASTROCYTOMAS 79
10.5 ACOUSTIC NEUROMA 80
10.6 OLIGODENDROGLIOMA 81
10.7 OLIGODENDROGLIOMA 81
10.8 OTHERS 82
11 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP 83
11.1 OVERVIEW 84
11.2 35-65 87
11.3 65 AND ABOVE 88
11.4 BELOW 21 89
11.5 21-34 90
12 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY END USER 91
12.1 OVERVIEW 92
12.2 HOSPITALS 95
12.3 SPECIALTY CLINICS 96
12.4 DIAGNOSTIC CENTERS & RESEARCH INSTITUTES 97
12.5 AMBULATORY SURGICAL CENTERS 98
12.6 OTHERS 99
13 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY REGION 100
13.1 OVERVIEW 101
13.2 NORTH AMERICA 106
13.2.1 U.S. 113
13.2.2 CANADA 115
13.2.3 MEXICO 117
13.3 EUROPE 119
13.3.1 GERMANY 126
13.3.2 FRANCE 128
13.3.3 U.K. 130
13.3.4 ITALY 132
13.3.5 SPAIN 134
13.3.6 RUSSIA 136
13.3.7 SWITZERLAND 138
13.3.8 NETHERLANDS 140
13.3.9 TURKEY 142
13.3.10 BELGIUM 144
13.3.11 REST OF EUROPE 146
13.4 ASIA-PACIFIC 147
13.4.1 CHINA 154
13.4.2 JAPAN 156
13.4.3 INDIA 158
13.4.4 AUSTRALIA 160
13.4.5 SOUTH KOREA 162
13.4.6 THAILAND 164
13.4.7 SINGAPORE 166
13.4.8 INDONESIA 168
13.4.9 MALAYSIA 170
13.4.10 PHILIPPINES 172
13.4.11 REST OF ASIA-PACIFIC 174
13.5 SOUTH AMERICA 175
13.5.1 BRAZIL 182
13.5.2 ARGENTINA 184
13.5.3 REST OF SOUTH AMERICA 186
13.6 MIDDLE EAST AND AFRICA 187
13.6.1 SOUTH AFRICA 194
13.6.2 SAUDI ARABIA 196
13.6.3 U.A.E. 198
13.6.4 KUWAIT 200
13.6.5 EGYPT 202
13.6.6 REST OF MIDDLE EAST AND AFRICA 204
14 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: COMPANY LANDSCAPE 205
14.1 COMPANY SHARE ANALYSIS: GLOBAL 205
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 206
14.3 COMPANY SHARE ANALYSIS: EUROPE 207
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 208
15 SWOT ANALYSIS 209
16 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, COMPANY PROFILE 210
16.1 KONINKLIJKE PHILIPS N.V. 210
16.1.1 COMPANY SNAPSHOT 210
16.1.2 REVENUE ANALYSIS 210
16.1.3 COMPANY SHARE ANALYSIS 211
16.1.4 PRODUCT PORTFOLIO 211
16.1.5 RECENT DEVELOPMENTS 212
16.2 CANON INC. 213
16.2.1 COMPANY SNAPSHOT 213
16.2.2 REVENUE ANALYSIS 213
16.2.3 COMPANY SHARE ANALYSIS 214
16.2.4 PRODUCT PORTFOLIO 214
16.2.5 RECENT DEVELOPMENT 214
16.3 SIEMENS HEALTHCARE GMBH 215
16.3.1 COMPANY SNAPSHOT 215
16.3.2 REVENUE ANALYSIS 216
16.3.3 COMPANY SHARE ANALYSIS 216
16.3.4 PRODUCT PORTFOLIO 217
16.3.5 RECENT DEVELOPMENTS 217
16.4 BD 218
16.4.1 COMPANY SNAPSHOT 218
16.4.2 REVENUE ANALYSIS 219
16.4.3 COMPANY SHARE ANALYSIS 219
16.4.4 PRODUCT PORTFOLIO 220
16.4.5 RECENT DEVELOPMENTS 220
16.5 NIHON KOHDEN CORPORATION. 221
16.5.1 COMPANY SNAPSHOT 221
16.5.2 RECENT FINANCIALS 221
16.5.3 COMPANY SHARE ANALYSIS 222
16.5.4 PRODUCT PORTFOLIO 222
16.5.5 RECENT DEVELOPMENT 222
16.6 BIOCEPT, INC. 223
16.6.1 COMPANY SNAPSHOT 223
16.6.2 REVENUE ANALYSIS 223
16.6.3 PRODUCT PORTFOLIO 224
16.6.4 RECENT DEVELOPMENT 224
16.7 BIOMIND 225
16.7.1 COMPANY SNAPSHOT 225
16.7.2 PRODUCT PORTFOLIO 225
16.7.3 RECENT DEVELOPMENT 225
16.8 CEREBRAL DIAGNOSTIC 226
16.8.1 COMPANY SNAPSHOT 226
16.8.2 PRODUCT PORTFOLIO 226
16.8.3 RECENT DEVELOPMENT 226
16.9 DXCOVER LIMITED 227
16.9.1 COMPANY SNAPSHOT 227
16.9.2 PRODUCT PORTFOLIO 227
16.9.3 RECENT DEVELOPMENT 227
16.10 FONAR CORP. 228
16.10.1 COMPANY SNAPSHOT 228
16.10.2 REVENUE ANALYSIS 228
16.10.3 PRODUCT PORTFOLIO 229
16.10.4 RECENT DEVELOPMENT 229
16.11 FUJIFILM CORPORATION 230
16.11.1 COMPANY SNAPSHOT 230
16.11.2 REVENUE ANALYSIS 230
16.11.3 PRODUCT PORTFOLIO 231
16.11.4 RECENT DEVELOPMENT 231
16.12 GE HEALTHCARE. 232
16.12.1 COMPANY SNAPSHOT 232
16.12.2 REVENUE ANALYSIS 232
16.12.3 PRODUCT PORTFOLIO 233
16.12.4 RECENT DEVELOPMENT 233
16.13 HITACHI, LTD. 234
16.13.1 COMPANY SNAPSHOT 234
16.13.2 REVENUE ANALYSIS 234
16.13.3 PRODUCT PORTFOLIO 235
16.13.4 RECENT DEVELOPMENT 235
16.14 MINFOUND MEDICAL SYSTEMS CO., 236
16.14.1 COMPANY SNAPSHOT 236
16.14.2 PRODUCT PORTFOLIO 236
16.14.3 RECENT DEVELOPMENT 236
16.15 NANTOMICS. 237
16.15.1 COMPANY SNAPSHOT 237
16.15.2 PRODUCT PORTFOLIO 237
16.15.3 RECENT DEVELOPMENT 237
16.16 NEUSOFT CORPORATION 238
16.16.1 COMPANY SNAPSHOT 238
16.16.2 REVENUE ANALYSIS 238
16.16.3 PRODUCT PORTFOLIO 239
16.16.4 RECENT DEVELOPMENT 239
16.17 SEQUOIA HEALTHCARE. 240
16.17.1 COMPANY SNAPSHOT 240
16.17.2 PRODUCT PORTFOLIO 240
16.17.3 RECENT DEVELOPMENT 240
16.18 STERNMED GMBH 241
16.18.1 COMPANY SNAPSHOT 241
16.18.2 PRODUCT PORTFOLIO 241
16.18.3 RECENT DEVELOPMENT 241
16.19 THERMO FISHER SCIENTIFIC INC. 242
16.19.1 COMPANY SNAPSHOT 242
16.19.2 REVENUE ANALYSIS 242
16.19.3 PRODUCT PORTFOLIO 243
16.19.4 RECENT DEVELOPMENT 243
16.20 TIME MEDICAL HOLDING. 244
16.20.1 COMPANY SNAPSHOT 244
16.20.2 PRODUCT PORTFOLIO 244
16.20.3 RECENT DEVELOPMENTS 244
17 QUESTIONNAIRE 245
18 RELATED REPORTS 248

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.